After being pressured by import tariffs of up to 31%, Swiss pharmaceutical giant Roche has taken a bold step by announcing a major investment worth €47 billion ($50 billion) in the United States (US) over the next five years.
According to reports, this investment will create 12,000 jobs including the creation of new R&D centers in California, Indiana, Massachusetts and Pennsylvania, as well as gene therapy facilities and the production of new generation weight loss drugs.
However, this statement that sounded ‘shocking’ began to cause ‘sus’ to some parties when the announcement suddenly appeared just a few hours after the Swiss President called Trump to discuss the tariff issue.
Even more suddenly when the White House suddenly ‘paused’ tariffs for 60 countries for 90 days.
Coincidence?
And in the midst of this suddenness, Roche CEO Thomas Schinecker suddenly added that they will export more drugs from the US without touching on the tariff issue.
In the midst of the hot tariff issue but no statement about tariffs has come out? Strange and miraculous.
Roche, which achieved almost €27 billion in pharmaceutical sales in the US last year, now has 24 operating sites in 8 states.
True! It seems that when economics and politics collide, who is good at timing and suddenly wakes up in a 10-year coma to sign an MoU!
